NZ514521A - Method of enhancing the efficacy of anti-tumor agents - Google Patents
Method of enhancing the efficacy of anti-tumor agentsInfo
- Publication number
- NZ514521A NZ514521A NZ514521A NZ51452100A NZ514521A NZ 514521 A NZ514521 A NZ 514521A NZ 514521 A NZ514521 A NZ 514521A NZ 51452100 A NZ51452100 A NZ 51452100A NZ 514521 A NZ514521 A NZ 514521A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tumor
- cisplatin
- epo
- hematocrit
- erythropoietin
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title abstract description 19
- 230000002708 enhancing effect Effects 0.000 title abstract description 6
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 81
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 81
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 81
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 80
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 58
- 229960004316 cisplatin Drugs 0.000 claims abstract description 57
- 238000005534 hematocrit Methods 0.000 claims abstract description 52
- 150000003058 platinum compounds Chemical class 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 11
- 229960004562 carboplatin Drugs 0.000 claims abstract description 7
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 13
- 230000000259 anti-tumor effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 10
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 34
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- 229910052697 platinum Inorganic materials 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000010437 erythropoiesis Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 3
- 206010036437 Posturing Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
- 102100036509 Erythropoietin receptor Human genes 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical class [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101100333654 Homo sapiens EPO gene Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- QGDXVUHJUWTGEF-UHFFFAOYSA-N cyclohexane-1,2-diamine;platinum(4+) Chemical class [Pt+4].NC1CCCCC1N QGDXVUHJUWTGEF-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000011395 multi-agent chemotherapy Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 208000014680 small intestine neoplasm Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/300,124 US6171620B1 (en) | 1999-04-27 | 1999-04-27 | Method of enhancing the efficacy of anti-tumor agents |
| PCT/US2000/011000 WO2000064455A1 (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ514521A true NZ514521A (en) | 2003-07-25 |
Family
ID=23157813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ514521A NZ514521A (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6171620B1 (enExample) |
| EP (1) | EP1212068A4 (enExample) |
| JP (1) | JP2002542296A (enExample) |
| KR (1) | KR100693796B1 (enExample) |
| CN (1) | CN1188137C (enExample) |
| AU (1) | AU781301B2 (enExample) |
| BG (1) | BG64940B1 (enExample) |
| BR (1) | BR0010082A (enExample) |
| CA (1) | CA2368618C (enExample) |
| HU (1) | HUP0200840A3 (enExample) |
| IL (1) | IL146012A0 (enExample) |
| MX (1) | MXPA01010899A (enExample) |
| NO (1) | NO20015227L (enExample) |
| NZ (1) | NZ514521A (enExample) |
| PL (1) | PL350918A1 (enExample) |
| RU (1) | RU2271829C2 (enExample) |
| WO (1) | WO2000064455A1 (enExample) |
| ZA (1) | ZA200108012B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| IL152428A0 (en) | 2000-04-26 | 2003-05-29 | Univ Kingston | Formulations and method of using nitric oxide mimetics against a malignant cell phenotype |
| US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| ES2528669T3 (es) | 2003-04-08 | 2015-02-11 | Progenics Pharmaceuticals, Inc. | Formulaciones farmacéuticas que contienen metilnaltrexona |
| DE10361813A1 (de) * | 2003-12-30 | 2005-09-08 | Bionethos Holding Gmbh | Verfahren zur Regeneration von Gewebe |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CA2600350C (en) * | 2005-03-07 | 2015-02-10 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| JP2010510794A (ja) | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| MX2009010515A (es) | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
| EP3263571B2 (en) | 2007-03-29 | 2023-08-23 | Progenics Pharmaceuticals, Inc. | Crystal form of (r)-n-methylnaltrexone bromide and uses thereof |
| JP5461386B2 (ja) | 2007-03-29 | 2014-04-02 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 末梢オピオイド受容体アンタゴニストおよびその使用 |
| US8471022B2 (en) | 2008-02-06 | 2013-06-25 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
| US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| CA2723621A1 (en) * | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| PL230756B1 (pl) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
| JPWO2019083023A1 (ja) * | 2017-10-26 | 2020-11-12 | 国立大学法人 筑波大学 | 癌の治療に使用するための組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2632014B2 (ja) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | 骨髄機能障害性貧血治療剤 |
| RU2111750C1 (ru) * | 1995-02-23 | 1998-05-27 | Институт элементоорганических соединений РАН | Модификатор для противоопухолевой терапии |
| JPH1067678A (ja) * | 1996-06-20 | 1998-03-10 | Chugai Pharmaceut Co Ltd | 肝疾患治療用医薬組成物 |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1999
- 1999-04-27 US US09/300,124 patent/US6171620B1/en not_active Expired - Fee Related
-
2000
- 2000-04-24 NZ NZ514521A patent/NZ514521A/en not_active IP Right Cessation
- 2000-04-24 PL PL00350918A patent/PL350918A1/xx not_active Application Discontinuation
- 2000-04-24 CN CNB008065659A patent/CN1188137C/zh not_active Expired - Fee Related
- 2000-04-24 IL IL14601200A patent/IL146012A0/xx unknown
- 2000-04-24 BR BR0010082-0A patent/BR0010082A/pt not_active Application Discontinuation
- 2000-04-24 HU HU0200840A patent/HUP0200840A3/hu unknown
- 2000-04-24 RU RU2001131894/14A patent/RU2271829C2/ru not_active IP Right Cessation
- 2000-04-24 WO PCT/US2000/011000 patent/WO2000064455A1/en not_active Ceased
- 2000-04-24 AU AU44863/00A patent/AU781301B2/en not_active Ceased
- 2000-04-24 EP EP00926315A patent/EP1212068A4/en not_active Withdrawn
- 2000-04-24 KR KR1020017012929A patent/KR100693796B1/ko not_active Expired - Fee Related
- 2000-04-24 JP JP2000613446A patent/JP2002542296A/ja active Pending
- 2000-04-24 MX MXPA01010899A patent/MXPA01010899A/es active IP Right Grant
- 2000-04-24 CA CA2368618A patent/CA2368618C/en not_active Expired - Fee Related
- 2000-12-19 US US09/740,501 patent/US6426094B2/en not_active Expired - Fee Related
-
2001
- 2001-09-28 ZA ZA200108012A patent/ZA200108012B/xx unknown
- 2001-10-25 NO NO20015227A patent/NO20015227L/no not_active Application Discontinuation
- 2001-10-26 BG BG106057A patent/BG64940B1/bg unknown
-
2002
- 2002-07-26 US US10/206,533 patent/US6620779B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2368618A1 (en) | 2000-11-02 |
| US6171620B1 (en) | 2001-01-09 |
| HUP0200840A3 (en) | 2003-04-28 |
| US6620779B2 (en) | 2003-09-16 |
| US20010000730A1 (en) | 2001-05-03 |
| CN1352561A (zh) | 2002-06-05 |
| CN1188137C (zh) | 2005-02-09 |
| PL350918A1 (en) | 2003-02-10 |
| RU2271829C2 (ru) | 2006-03-20 |
| KR100693796B1 (ko) | 2007-03-12 |
| MXPA01010899A (es) | 2003-06-24 |
| AU4486300A (en) | 2000-11-10 |
| CA2368618C (en) | 2011-03-01 |
| AU781301B2 (en) | 2005-05-12 |
| NO20015227L (no) | 2001-12-27 |
| BR0010082A (pt) | 2002-01-15 |
| KR20020000557A (ko) | 2002-01-05 |
| HUP0200840A2 (hu) | 2002-07-29 |
| BG106057A (en) | 2002-04-30 |
| BG64940B1 (bg) | 2006-10-31 |
| NO20015227D0 (no) | 2001-10-25 |
| EP1212068A4 (en) | 2007-03-14 |
| US6426094B2 (en) | 2002-07-30 |
| JP2002542296A (ja) | 2002-12-10 |
| ZA200108012B (en) | 2003-03-26 |
| IL146012A0 (en) | 2002-07-25 |
| US20020198153A1 (en) | 2002-12-26 |
| EP1212068A1 (en) | 2002-06-12 |
| WO2000064455A1 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2368618C (en) | Method of enhancing the efficacy of anti-tumor agents | |
| Abdel-Razeq et al. | Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia | |
| EP0224885B1 (en) | Antitumor composition. | |
| Kim et al. | Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice | |
| KR101413731B1 (ko) | 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물 | |
| AU2012257760A1 (en) | Method for treatment of advanced solid tumors | |
| CN1349406A (zh) | 含吗啉蒽环类化生物和抗癌剂的联合制剂 | |
| Batist et al. | Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. | |
| JPH0296523A (ja) | 白金化学療法生成物 | |
| EP1729808B1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 | |
| Gonzalez et al. | Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma | |
| Ford et al. | Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. | |
| EP3965734A1 (en) | Method for increasing cancer patient's haemoglobin level | |
| CN112168971B (zh) | 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用 | |
| CN113679720B (zh) | 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途 | |
| Kolesar | Novel approaches to anemia associated with cancer and chemotherapy | |
| Inoue et al. | Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice | |
| Bellamy | Fundamental concepts associated with combining cytotoxic drugs and x-irradiation | |
| WO2024216238A2 (en) | Use of beta-catenin antagonist and immunomodulator | |
| Ellerby et al. | Preliminary Report on Phase 1 Clinical Experience with Combined cis-diamminedichloride Platinum (II)(PDD) and 5-FU | |
| CN117398467A (zh) | 一种预防或治疗滤泡淋巴瘤的联合用药物组合物及其应用 | |
| Weiss et al. | A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer | |
| JPH06116164A (ja) | 癌の併用化学療法剤 | |
| CN112168960A (zh) | 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用 | |
| Lévi et al. | and Folinic Acid (Leucovorin) in Patients With Colorectal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| LAPS | Patent lapsed |